Press Releases March 30, 2026 08:00 PM

InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference

InspireMD to present at the 25th Annual Needham Virtual Healthcare Conference

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
NSPR

InspireMD, Inc., developer of the CGuard Prime carotid stent system, announced its participation in the 25th Annual Needham Virtual Healthcare Conference with a presentation scheduled for April 14th. The event will be webcast live and archived on InspireMD's corporate website.

InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference
NSPR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • InspireMD will present at a prominent healthcare investment conference, increasing its visibility among investors.
  • The company focuses on its proprietary MicroNet mesh technology aimed at improving carotid stenting outcomes to prevent strokes.
  • The presentation includes live audio webcast and online archive, facilitating broad investor access.

MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14th at 12:45 pm Eastern Time (ET).

A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD’s corporate website at https://investors.inspiremd.com.

About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.

Investor Contacts:
Webb Campbell
Gilmartin Group LLC
[email protected]
[email protected]


Risks

  • Market response to the conference presentation is uncertain, and no new clinical or financial data is indicated in the announcement.
  • The success of InspireMD's proprietary technology depends on clinical adoption and regulatory factors in the medical devices sector.
  • Competition in the carotid stent and stroke prevention market could impact InspireMD's market share and growth potential.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026